from 31 Mar 2012 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: HERON THERAPEUTICS, INC. /DE/ quarterly Debt-to-equity in % history and change rate from 31 Mar 2012 to 31 Dec 2025.
HERON THERAPEUTICS, INC. /DE/ Debt-to-equity for the quarter ending 31 Dec 2025 was -3771%, a 430% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

HERON THERAPEUTICS, INC. /DE/ Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	-3771%	-3059%	-430%	31 Dec 2025
Q3 2025	-1375%	-672%	-96%	30 Sep 2025
Q2 2025	-813%	-47%	-6.2%	30 Jun 2025
Q1 2025	-748%	-2.2%	-0.3%	31 Mar 2025
Q4 2024	-712%	+165%	+19%	31 Dec 2024
Q3 2024	-704%	+786%	+53%	30 Sep 2024
Q2 2024	-765%	+5767%	+88%	30 Jun 2024
Q1 2024	-746%	-35219%	-102%	31 Mar 2024
Q4 2023	-877%	-3498%	-133%	31 Dec 2023
Q3 2023	-1490%	-2461%	-253%	30 Sep 2023
Q2 2023	-6533%	-7024%	-1428%	30 Jun 2023
Q1 2023	34473%	+34222%	+13626%	31 Mar 2023
Q4 2022	2621%	+2472%	+1666%	31 Dec 2022
Q3 2022	971%	+872%	+874%	30 Sep 2022
Q2 2022	492%	+424%	+627%	30 Jun 2022
Q1 2022	251%	+207%	+473%	31 Mar 2022
Q4 2021	148%	+111%	+295%	31 Dec 2021
Q3 2021	100%	+67%	+208%	30 Sep 2021
Q2 2021	68%	+36%	+113%	30 Jun 2021
Q1 2021	44%	+12%	+37%	31 Mar 2021
Q4 2020	38%	+5.4%	+17%	31 Dec 2020
Q3 2020	32%	+0.69%	+2.2%	30 Sep 2020
Q2 2020	32%			30 Jun 2020
Q1 2020	32%			31 Mar 2020
Q4 2019	32%			31 Dec 2019
Q3 2019	32%			30 Sep 2019
Q4 2017	100%			31 Dec 2017
Q3 2017	172%			30 Sep 2017
Q2 2017	197%			30 Jun 2017
Q1 2012	20%			31 Mar 2012

* An asterisk sign (*) next to the value indicates that the value is likely invalid.